Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection

PHASE4RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

August 22, 2026

Study Completion Date

August 30, 2026

Conditions
EBV Infection
Interventions
DRUG

2LEBV® / 2LXFS®

The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

DRUG

Placebo

The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

Trial Locations (12)

1040

RECRUITING

Private Practice, Brussels

RECRUITING

Private practice, Brussels

1090

WITHDRAWN

Private Practice, Jette

1200

RECRUITING

Private Practice, Brussels

1300

WITHDRAWN

Private Practice, Limal

2630

RECRUITING

Private Practice, Aartselaar

2900

RECRUITING

Cabinet privé, Schoten

3190

TERMINATED

Private Practice, Boortmeerbeek

4790

RECRUITING

Private practice, Stavelot

6900

RECRUITING

Private practice, Marche-en-Famenne

8790

RECRUITING

Private practice, Waregem

9000

RECRUITING

Private Practice, Ghent

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Labo'Life

INDUSTRY